Article
The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
PharmacoEconomics - 1 Nov 2012
Panattoni Laura, Brown Paul M, Te Ao Braden, Webster Mark, Gladding Patrick
Abstract excerpt
BACKGROUND: A recent clinical trial has demonstrated that patients with acute coronary syndromes (ACS) and the reduced function allele CYP2C19*2 (*2 allele), who are treated with thienopyridines, have an increased risk of adverse cardiac events with clopidogrel, but not with prasugrel. The freque...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.